AWM Investment Company Inc. Boosts Stock Holdings in Alto Neuroscience, Inc. $ANRO

Key Points

• AWM Investment Company Inc. increased its stake in Alto Neuroscience by 31.1% during the first quarter, owning about 3.33% of the company’s equity, valued at nearly $1.95 million.
• Alto Neuroscience has received mixed analyst ratings, with a consensus price target of $8.50 and four analysts rating it as a "Buy".
• The company's latest earnings report showed a loss of ($0.65) per share, which was below analysts' expectations, forecasting an annual EPS of -2.54.

AWM Investment Company Inc. lifted its position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 31.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 901,984 shares of the company's stock after buying an additional 214,153 shares during the period. AWM Investment Company Inc. owned approximately 3.33% of Alto Neuroscience worth $1,948,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Armistice Capital LLC increased its holdings in Alto Neuroscience by 146.2% in the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock worth $3,456,000 after acquiring an additional 950,000 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Alto Neuroscience by 73.1% in the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company's stock valued at $7,158,000 after acquiring an additional 714,461 shares in the last quarter. Woodline Partners LP raised its holdings in Alto Neuroscience by 397.6% during the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company's stock worth $2,631,000 after purchasing an additional 496,976 shares in the last quarter. Northern Trust Corp grew its position in shares of Alto Neuroscience by 198.1% during the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company's stock worth $2,484,000 after acquiring an additional 390,190 shares during the last quarter. Finally, Integral Health Asset Management LLC purchased a new position in shares of Alto Neuroscience during the fourth quarter worth approximately $1,269,000.

Wall Street Analysts Forecast Growth

ANRO has been the subject of several analyst reports. Wedbush reissued a "neutral" rating and issued a $4.00 target price on shares of Alto Neuroscience in a research note on Thursday, May 15th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Alto Neuroscience in a research note on Monday, August 18th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

Alto Neuroscience Trading Up 3.8%

NYSE:ANRO traded up $0.14 on Friday, reaching $3.65. The company's stock had a trading volume of 36,319 shares, compared to its average volume of 83,860. The firm has a market cap of $98.71 million, a PE ratio of -1.53 and a beta of 1.91. The business's 50-day moving average price is $3.10 and its two-hundred day moving average price is $2.74. Alto Neuroscience, Inc. has a 1-year low of $1.60 and a 1-year high of $15.04. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Equities research analysts anticipate that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.